Xcel Wealth Management LLC Makes New Investment in Kura Oncology, Inc. $KURA

Xcel Wealth Management LLC purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 102,321 shares of the company’s stock, valued at approximately $906,000.

Other large investors have also recently modified their holdings of the company. Merit Financial Group LLC purchased a new stake in Kura Oncology during the third quarter valued at approximately $89,000. Tower Research Capital LLC TRC grew its holdings in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares during the last quarter. Brighton Jones LLC acquired a new position in shares of Kura Oncology during the third quarter worth $108,000. Pallas Capital Advisors LLC lifted its holdings in shares of Kura Oncology by 32.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock valued at $77,000 after purchasing an additional 3,241 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Kura Oncology in the 2nd quarter worth $80,000.

Kura Oncology Stock Performance

KURA opened at $8.46 on Monday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49. The firm has a 50 day moving average of $10.63 and a two-hundred day moving average of $8.92. The firm has a market capitalization of $736.19 million, a PE ratio of -3.41 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. On average, analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In related news, COO Kathleen Ford sold 6,902 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $77,164.36. Following the completion of the transaction, the chief operating officer directly owned 105,373 shares in the company, valued at $1,178,070.14. The trade was a 6.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Francis Burrows sold 23,726 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.78, for a total transaction of $232,040.28. Following the sale, the insider directly owned 33,735 shares in the company, valued at $329,928.30. This trade represents a 41.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 68,343 shares of company stock valued at $730,858. 6.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Leerink Partners set a $20.00 price target on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Barclays restated an “overweight” rating and set a $28.00 price target (up previously from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.